| Peer-Reviewed

Multiple Myeloma Treatments, Outcomes, and Costs of Health Care Resource Utilisation During 2009-2016, Based on Multiple Data Sources from a Hospital District in Finland

Received: 31 December 2020     Accepted: 11 January 2021     Published: 28 January 2021
Views:       Downloads:
Abstract

Multiple myeloma (MM) is one of the most prevalent hematologic cancers. Treatments of MM have been improved by availability of novel therapies but require regular hospital visits and intense patient follow-up. In this real-world study, patient characteristics, first four treatment lines (1L–4L), and associated outcomes and costs were assessed among adults treated for active MM during 2009–2016 at Kymenlaakso Central Hospital, Kymsote hospital district, Finland. In addition, patient burden and travel costs were determined for the patients treated during 2015–2016. Ninety-seven patients fulfilled the inclusion criteria. Data were retrospectively collected from hospital’s database, medical charts, and from healthcare professionals. Treatment lines and responses were defined according to the general recommendations. The median age at diagnosis was 70.1 years. The median overall survival was 68 months. Proteasome inhibitors (PI) or immunomodulatory drugs (IM) were the most common regimen types while the utilisation of a more novel approach, the simultaneous use of PI and IM, was low across first four treatment lines. Overall response rate was 72–74% for 1L–2L and 50–56% for 3L–4L. Drug costs represented the greatest proportion of total healthcare costs and increased in the later treatment lines. Patients receiving infusion treatments had specialised health care visits twice as much the patients treated with oral treatments. Furthermore, travel costs related to infusion treatments were three to four times more compared to the respective costs for oral treatments. Increasing drug costs but poorer treatment outcomes in later treatment lines underline a need for more efficient and better tolerated treatment options. This study demonstrates that oral treatments may indeed reduce patient and hospital resource burden and thus, should be considered in future health economic evaluations in Finland.

Published in International Journal of Clinical and Experimental Medical Sciences (Volume 7, Issue 1)
DOI 10.11648/j.ijcems.20210701.14
Page(s) 21-30
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Healthcare Costs, Line of Treatment, Multiple Myeloma, Oral Treatment, Survival, Treatment Outcome

References
[1] Röllig C, Knop S, Bornhäuser M. Multiple myeloma. The Lancet. 2015; 385: 2197–2208.
[2] Barwick BG, Gupta VA, Vertino PM, et al. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front Immunol. 2019; 10: 1121.
[3] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014; 15: e538–e548.
[4] The National Cancer Institute (NCI). The Surveillance, Epidemiology, and End Results (SEER). [Internet]. The National Cancer Institute. 2020 [cited 2020 Jul 7]. Available from: https://cancer.gov.
[5] ECIS - European Cancer Information System [Internet]. European Union. 2018 [cited 2020 Jul 8]. Available from: https://ecis.jrc.ec.europa.eu.
[6] The Finnish Cancer Registry. Statistics and Research. [Internet]. The Finnish Cancer Registry. 2020 [cited 2020 Jul 8]. Available from: https://cancerregistry.fi/.
[7] Kolovos S, Nador G, Kishore B, et al. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. Journal of Bone Oncology. 2019; 17: 100243.
[8] Scelo G, Li P, Chanudet E, et al. Variability of Sex Disparities in Cancer Incidence over 30 Years: The Striking Case of Kidney Cancer. European Urology Focus. 2018; 4: 586–590.
[9] Cowan AJ, Allen C, Barac A, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018; 4: 1221.
[10] Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood. 2015; 125: 410–412.
[11] Sinisalo, Marjatta, Laine, Outi. Myelooma [Internet]. Duodecim Terveysportti health portal. 2018 [cited 2020 Feb 26]. Available from: https://www.terveysportti.fi/apps/ltk/ykt00388?toc=23075.
[12] Säily, Marjaana, Silvennoinen, Raija, Jantunen, Esa, et al. Monimuotoinen myelooma. Duodecim. 2019; 135: 1171–1179.
[13] Putkonen M, Silvennoinen R. Multippeli myelooma ja muut gammapatiat. In: Porkka K, Lassila R, Remes K, Savolainen E-R, editors. Veritaudit. 4th ed. Helsinki: Duodecim 2015; p. 403–434.
[14] Finnish Hematology Association (SHY) [Internet]. Finnish Hematology Association (SHY). 2020 [cited 2020 Jul 6]. Available from: https://www.hematology.fi/fi.
[15] Hagiwara M, Panjabi S, Delea T, et al. Burden of disease progression in patients with multiple myeloma in the US. Leukemia & Lymphoma. 2019; 1–9.
[16] Kumar SK, Callander NS, Alsina M, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018; 16: 11–20.
[17] Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017; 28: iv52–iv61.
[18] Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516–2520.
[19] Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Seminars in Oncology. 2016; 43: 676–681.
[20] Ludwig H, Beksac M, Blade J, et al. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. The Oncologist. 2010; 15: 6–25.
[21] Raju GK, Gurumurthi K, Domike R, et al. A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma. Clin Pharmacol Ther. 2018; 103: 67–76.
[22] Remes K, Anttila P, Silvennoinen R, et al. Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013. Bertolini F, editor. PLoS ONE. 2018; 13: e0208507.
[23] Petrakis I, Kontogiorgis C, Nena E, et al. Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma. Expert Review of Hematology. 2019; 12: 1063–1075.
[24] Jagannath S, Roy A, Kish J, et al. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Review of Hematology. 2016; 9: 707–717.
[25] Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Current Medical Research and Opinion. 2016; 32: 95–103.
[26] Teitelbaum A, Ba-Mancini A, Huang H, et al. Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data. The Oncologist. 2013; 18: 37–45.
[27] Clancy Z, Pandya S, Shrestha S, et al. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts). JCO. 2018; 36: 194–194.
[28] Mankinen P, Vihervaara V, Torvinen S, et al. Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland. Journal of Medical Econosmics. 2019; 22: 328–335.
[29] Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. JCO. 2015; 33: 2863–2869.
[30] Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117: 4691–4695.
[31] Leleu X, Mateos M-V, Delforge M, et al. Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study. Blood. 2015; 126: 2086–2086.
[32] Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016; 10: 1609–1621.
[33] WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects [Internet]. The World Medical Association, Inc. 2018 [cited 2019 Oct 18]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.
Cite This Article
  • APA Style

    Saku Torvinen, Ville Vihervaara, Tatu Miettinen, Jari Jokelainen, Melissa Bauer, et al. (2021). Multiple Myeloma Treatments, Outcomes, and Costs of Health Care Resource Utilisation During 2009-2016, Based on Multiple Data Sources from a Hospital District in Finland. International Journal of Clinical and Experimental Medical Sciences, 7(1), 21-30. https://doi.org/10.11648/j.ijcems.20210701.14

    Copy | Download

    ACS Style

    Saku Torvinen; Ville Vihervaara; Tatu Miettinen; Jari Jokelainen; Melissa Bauer, et al. Multiple Myeloma Treatments, Outcomes, and Costs of Health Care Resource Utilisation During 2009-2016, Based on Multiple Data Sources from a Hospital District in Finland. Int. J. Clin. Exp. Med. Sci. 2021, 7(1), 21-30. doi: 10.11648/j.ijcems.20210701.14

    Copy | Download

    AMA Style

    Saku Torvinen, Ville Vihervaara, Tatu Miettinen, Jari Jokelainen, Melissa Bauer, et al. Multiple Myeloma Treatments, Outcomes, and Costs of Health Care Resource Utilisation During 2009-2016, Based on Multiple Data Sources from a Hospital District in Finland. Int J Clin Exp Med Sci. 2021;7(1):21-30. doi: 10.11648/j.ijcems.20210701.14

    Copy | Download

  • @article{10.11648/j.ijcems.20210701.14,
      author = {Saku Torvinen and Ville Vihervaara and Tatu Miettinen and Jari Jokelainen and Melissa Bauer and Anu Marttila and Klaus Tamminen and Jonna Salonen},
      title = {Multiple Myeloma Treatments, Outcomes, and Costs of Health Care Resource Utilisation During 2009-2016, Based on Multiple Data Sources from a Hospital District in Finland},
      journal = {International Journal of Clinical and Experimental Medical Sciences},
      volume = {7},
      number = {1},
      pages = {21-30},
      doi = {10.11648/j.ijcems.20210701.14},
      url = {https://doi.org/10.11648/j.ijcems.20210701.14},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20210701.14},
      abstract = {Multiple myeloma (MM) is one of the most prevalent hematologic cancers. Treatments of MM have been improved by availability of novel therapies but require regular hospital visits and intense patient follow-up. In this real-world study, patient characteristics, first four treatment lines (1L–4L), and associated outcomes and costs were assessed among adults treated for active MM during 2009–2016 at Kymenlaakso Central Hospital, Kymsote hospital district, Finland. In addition, patient burden and travel costs were determined for the patients treated during 2015–2016. Ninety-seven patients fulfilled the inclusion criteria. Data were retrospectively collected from hospital’s database, medical charts, and from healthcare professionals. Treatment lines and responses were defined according to the general recommendations. The median age at diagnosis was 70.1 years. The median overall survival was 68 months. Proteasome inhibitors (PI) or immunomodulatory drugs (IM) were the most common regimen types while the utilisation of a more novel approach, the simultaneous use of PI and IM, was low across first four treatment lines. Overall response rate was 72–74% for 1L–2L and 50–56% for 3L–4L. Drug costs represented the greatest proportion of total healthcare costs and increased in the later treatment lines. Patients receiving infusion treatments had specialised health care visits twice as much the patients treated with oral treatments. Furthermore, travel costs related to infusion treatments were three to four times more compared to the respective costs for oral treatments. Increasing drug costs but poorer treatment outcomes in later treatment lines underline a need for more efficient and better tolerated treatment options. This study demonstrates that oral treatments may indeed reduce patient and hospital resource burden and thus, should be considered in future health economic evaluations in Finland.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Multiple Myeloma Treatments, Outcomes, and Costs of Health Care Resource Utilisation During 2009-2016, Based on Multiple Data Sources from a Hospital District in Finland
    AU  - Saku Torvinen
    AU  - Ville Vihervaara
    AU  - Tatu Miettinen
    AU  - Jari Jokelainen
    AU  - Melissa Bauer
    AU  - Anu Marttila
    AU  - Klaus Tamminen
    AU  - Jonna Salonen
    Y1  - 2021/01/28
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ijcems.20210701.14
    DO  - 10.11648/j.ijcems.20210701.14
    T2  - International Journal of Clinical and Experimental Medical Sciences
    JF  - International Journal of Clinical and Experimental Medical Sciences
    JO  - International Journal of Clinical and Experimental Medical Sciences
    SP  - 21
    EP  - 30
    PB  - Science Publishing Group
    SN  - 2469-8032
    UR  - https://doi.org/10.11648/j.ijcems.20210701.14
    AB  - Multiple myeloma (MM) is one of the most prevalent hematologic cancers. Treatments of MM have been improved by availability of novel therapies but require regular hospital visits and intense patient follow-up. In this real-world study, patient characteristics, first four treatment lines (1L–4L), and associated outcomes and costs were assessed among adults treated for active MM during 2009–2016 at Kymenlaakso Central Hospital, Kymsote hospital district, Finland. In addition, patient burden and travel costs were determined for the patients treated during 2015–2016. Ninety-seven patients fulfilled the inclusion criteria. Data were retrospectively collected from hospital’s database, medical charts, and from healthcare professionals. Treatment lines and responses were defined according to the general recommendations. The median age at diagnosis was 70.1 years. The median overall survival was 68 months. Proteasome inhibitors (PI) or immunomodulatory drugs (IM) were the most common regimen types while the utilisation of a more novel approach, the simultaneous use of PI and IM, was low across first four treatment lines. Overall response rate was 72–74% for 1L–2L and 50–56% for 3L–4L. Drug costs represented the greatest proportion of total healthcare costs and increased in the later treatment lines. Patients receiving infusion treatments had specialised health care visits twice as much the patients treated with oral treatments. Furthermore, travel costs related to infusion treatments were three to four times more compared to the respective costs for oral treatments. Increasing drug costs but poorer treatment outcomes in later treatment lines underline a need for more efficient and better tolerated treatment options. This study demonstrates that oral treatments may indeed reduce patient and hospital resource burden and thus, should be considered in future health economic evaluations in Finland.
    VL  - 7
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Takeda Oy, Helsinki, Finland

  • Takeda Oy, Helsinki, Finland

  • Medaffcon Oy, Espoo, Finland

  • MedEngine Oy, Helsinki, Finland

  • Takeda Oy, Helsinki, Finland

  • Kymenlaakso Central Hospital, Kotka, Finland

  • Takeda Oy, Helsinki, Finland

  • Kymenlaakso Central Hospital, Kotka, Finland

  • Sections